A new study indicates that exposure to a particular scent can enhance the immune system and boost cognitive function in animals affected by this neurodegenerative disorder. This paves the way for new therapeutic approaches that leverage olfactory stimulation and training as a method to combat or alleviate the impacts of Alzheimer’s and other central nervous system diseases.
Scientists from Cima University of Navarra in Spain have demonstrated through experiments on animal models of Alzheimer’s disease that menthol inhalation enhances cognitive performance. Their research indicated that frequent, brief exposure to this substance can adjust the immune response and prevent the typical cognitive decline associated with this neurodegenerative disorder.
In their examination of how menthol works, the scientists noted a decrease in interleukin-1-beta (IL-1b) levels when the scent was detected. IL-1b is a key protein involved in the inflammatory response. Furthermore, when they used a medication approved for managing certain autoimmune conditions to suppress this protein, it also resulted in improved cognitive skills in the afflicted mice.
This research highlights the potential of odors and immune modulators as therapeutic agents. Furthermore, it opens the door to developing therapies based on stimulating and training the olfactory system to prevent or alleviate the effects of Alzheimer’s and other diseases of the central nervous system. Frontiers in Immunology published the results of this study in its latest issue.
Brain, smell, and immune system connection
The functional balance of the brain depends on complex interactions between various types of nerve cells, immune cells, and neural stem cells. In this complex web of interactions, several studies have addressed the immunomodulatory and neurological effects of odorants. Other previous works have also shown a correlation between the loss of the sense of smell and the appearance of the first symptoms of Alzheimer’s disease.
“We have focused on the olfactory system’s role in the immune and central nervous systems, and we have confirmed that menthol is an immunostimulatory odor in animal models. But, surprisingly, we observed that short exposures to this substance for six months prevented cognitive decline in the mice with Alzheimer’s and, what is most interesting, also improved the cognitive ability of healthy young mice,” says Dr. Juan José Lasarte, director of the Immunology and Immunotherapy Program at Cima and principal author of the investigation.
Another result noted by the researchers is that “blocking the activity of T regulatory cells, one type of immune cells with immunosuppressive activity, also improved the cognitive ability of mice with Alzheimer’s disease and also caused a clear benefit in the cognitive ability of healthy young mice,” explains Dr. Ana García-Osta, a researcher at Cima’s Gene Therapy of Neurological Diseases Program and principal co-author of this work. “Both menthol exposure and Treg cell blockade caused a decrease in IL-1b, a protein that could be behind the cognitive decline observed in these models. In addition, the specific blockade of this protein with a drug used in treating some autoimmune diseases also improved the cognitive capacity of healthy mice and mice with Alzheimer’s”.
“This study is an important step toward understanding the connection between the immune system, the central nervous system, and smell, as the results suggest that odors and immune modulators may play an important role in the prevention and treatment of Alzheimer’s.” and other diseases related to the central nervous system,” points out Dr. Noelia Casares, also a researcher at the Immunology and Immunotherapy Program and first author of the article.
Reference: “Improvement of cognitive function in wild-type and Alzheimer´s disease mouse models by the immunomodulatory properties of menthol inhalation or by depletion of T regulatory cells” by Noelia Casares, María Alfaro, Mar Cuadrado-Tejedor, Aritz Lasarte-Cia, Flor Navarro, Isabel Vivas, María Espelosin, Paz Cartas-Cejudo, Joaquín Fernández-Irigoyen, Enrique Santamaría, Ana García-Osta and Juan José Lasarte, 27 April 2023, Frontiers in Immunology.
The Government of Navarra and the Ministry of Economy and Competitiveness financed this work. It is part of the Instituto de Investigación Santiaria de Navarra (IdiSNA). It is also part of the INNOLFACT project, a multicenter consortium coordinated by Dr Enrique Santamaría, a Navarrabiomed researcher. This consortium aims to study the olfactory function in aging and develop new immunomodulatory therapies to slow down the development of neurodegenerative diseases.